Tag: Addictions

We found 67 articles matching your criteria
  1. What happened at the CND61?

    21/03/2018

    The organized civil society is now playing an important role at the United Nations Commission on Narcotic Drugs

  2. 16th Conference of EFTC

    17/10/2017

    16th Conference of the European Federation of Therapeutic Communities: Pathways of care to recovery

  3. Thematic Discussions at the CND

    06/10/2017

    The Commission on Narcotic Drugs (CND) organized a series of thematic discussions on the implementation outcome document of UNGASS

  4. State of Play on the World Drug Problem

    27/07/2017

    Based on the findings of the World Drug Report 2016, Cannabis remains the most commonly used drug at the global level, while amphetamines is the second most commonly used drug

  5. Seminar on “Women & Drugs”

    24/07/2017

    “Women and Drugs: From Policy to Good Practice”, a seminar organized in Rome, in June 2017

  6. The Dianova Network Welcomes 4 New Members

    04/07/2017

    The Association of Youth Commited to Humanitarian Action (Togo), the European Center for Addiction Prevention (Romania), Active Women for Environmental Protection (DRC) and RIO (Norway), become associate members of Dianova International

  7. 19th Ibero-American Seminar on Drugs and Cooperation

    23/05/2017

    The seminar organized by the Ibero-American Network of NGOs working in the fields of Drugs and Other Addictions (RIOD) took place in San José, Costa Rica

  8. 61st Session of the CICAD

    10/05/2017

    Building up on UNGASS recommendations for measurable and evidence based approaches to drug policies and programs

  9. Interview with Antonio J. Molina

    10/04/2017

    “It is important that we develop more visibility in the activities of civil society, and CND60 has been successful in this.” – Antonio J. Molina, Therapeutic Coordinator at Dianova Spain

  10. Recovery Exhibition at the CND

    05/04/2017

    The #WeDoRecover” exhibition focused on the issue “Recovery in communities” to give visibility and promote recovery-oriented drug policies